Pluristem Therapeutics concludes preclinical safety studies of ischemia drug
The final studies involved 150 animals that received single, repeated intra-muscular injections of PLX-PAD or a control substance then followed for up to three months post-injection. No adverse
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.